Oncoinvent presents 3Q company update in live webcast

Oslo, Norway, 28 October 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is hosting a live webcast at 10:00 AM CET today, Wednesday, 28 October 2026.

• Presenters: CEO Øystein Soug, CFO Ramzi Amri, CMO Zuzana Jirakova Trnkova
• Time: 10:00am CET
• Webcast link: https://qcnl.tv/p/8awn9AmyNjOd67OuY7TwRQ   

Highlights:

• Recruited 16 patients into the ovarian Phase 2 trial, having a total of 71 patients by end 3Q
• Added one more clinical site to Oncoinvent’s Phase 2 trial; 11 clinical sites now recruiting
• Published Normal tissue dosimetry results in Journal of Nuclear Medicine
• Presented three abstracts at EANM and ESMO
• Completed successful private placement raising gross proceeds of NOK 148.5 million
• Appointed Dr Zuzana Jirakova Trnkova as Chief Medical Offier

The presentation material and the recording of the webcast will be made available at www.oncoinvent.com.

Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.